Valore clinico dei nuovi dati biologici

Published: June 8, 2009
Abstract Views: 826
PDF: 9860
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

La diagnosi di malattia mieloproliferativa cronica (MMPC) Philadelphia-negativa si basa sui criteri stabiliti dalla classificazione WHO.1 Tale classificazione ha introdotto l’impiego della biopsia osteomidollare come procedura principale per la diagnosi di trombocitemia essenziale (TE) e mielofibrosi idiopatica (CIMF) e come procedura secondaria per la diagnosi di policitemia vera (PV).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Boveri, E., Castello, A., Passamonti, B. F., Rumi, E., Elena, C., Lazzarino, M., & Cazzola, M. (2009). Valore clinico dei nuovi dati biologici. Hematology Meeting Reports (formerly Haematologica Reports), 2(6). https://doi.org/10.4081/hmr.v2i6.387